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Introduction
 Upper respiratory tract infections (URTI) are highly incident infectious diseases, which affect adults 2-5 times per year[1]. 
These infections include common cold, sore throat, sinusitis, laryngitis and otitis media and may involve several regions of the upper 
respiratory tract simultaneously. 
 URTI comprises seasonal infections, many prevailing during winter season[2]. Several factors may predispose an individual 
to acquire these diseases, including his immune state, exposure to pollution or smoking and asthma[3,4]. Although some studies have 
confirmed the impact of allergy on rhinosinusitis resulting from a higher number of receptors for rhinovirus on allergic patients, the 
role of allergy as a predisposing factor for URTI is controversial[3]. Furthermore, gastroesophageal reflux disease (GERD) may also 
induce respiratory symptoms (eg. chronic cough), resulting from bronchoconstriction through vagal reflex or by aspiration. Even 
though GERD can lead to misdiagnosis, it is also considered as a predisposing factor for URTI triggered by chemical injury[5].
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Abstract
Objectives: To empirically classify the etiology of URTI; to study the prescription 
pattern for antibiotics in URTI; and to analyze the necessity and adequacy of pre-
scribed therapy.
Study design: Observational non analytical cross-sectional study.
Study sites: Two community pharmacies located in Almada and in Elvas.
Study population: Patients with an antibiotic prescription for a URTI (self use) and 
age greater than or equal to 18 years. 
Methods: Clinical and therapeutic data were collected during patient observation 
performed by a training pharmacist, and complemented with information collected 
through a questionnaire administered face-to-face to patients meeting the inclusion 
criteria and agreeing to participate. Empirical classifications were developed, one to 
ascertain the probability of URTI, based on Centor criteria, and another, to judge the 
need for antibiotic therapy, based on additional criteria considering subpopulations 
known to be at higher risk. Data was analyzed using the software SPSS, version 20.0.
Results: The sample included 22 patients (27.3% recruited in Almada and 72.7% in 
Elvas). The most frequently prescribed antibiotic class was macrolides (54.5%), fol-
lowed by penicillins (36.4%). In the first group, clarithromycin prevailed (66.7%) and 
in the second group, the more common was the association amoxicillin/clavulanic acid 
(75%). Considering the empirical classification developed, it was estimated that only 
one patient (4.5%) presented signs and symptoms suggestive of URTI with probable 
bacterial aetiology, and only three patients (13.6%) had an indication for antimicrobial 
therapy.
Conclusion: The majority of patients observed were classified as having infections 
with apparently non-bacterial aetiology, for which the prescription of antibiotic would 
have been probably needless. This alerts to the overuse of antibiotics in the community 
setting, particularly for URTI, and its contribution to resistance.
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2Although it is relatively difficult to establish a differential diag-
nosis in pharyngitis, the Centor criteria are highly recognized 
and commonly used during patient observation. These criteria 
consider the signs and symptoms most commonly involved in 
pharyngitis, which can be summarised by: presence of pharyn-
geal exudates, anterior cervical adenopathy, fever and the ab-
sence of cough. Consequently, in the presence of at least three 
of these features, it is possible to predict that the infection is 
probably of bacterial origin[6].
 Rhinosinusitis can be classified as acute sinusitis, when 
the duration of the symptoms is less than one month; subacute, 
when the symptoms persist for twelve weeks, and chronic when 
exceeding twelve weeks. Sinusitis may also be classified as re-
current when the individual presents four or more episodes per 
year[7].
 Antibiotic treatment instituted in these URTI is essen-
tially empirical since the microbiological diagnosis is rarely 
made, due to the time limitations, difficulty in obtaining clinical 
samples (sinusitis) and costs of rapid tests (e.g. rapid antigen 
detection test for group A streptococcus)[8,9]. Taking into account 
that URTI are frequently caused by respiratory viruses, antibiot-
ic therapy proves to be unnecessary in most of the cases. Nev-
ertheless, antimicrobials are used mainly to prevent potential 
complications that may arise from non-antibiotic indication. In 
Portugal, primary care prescription focuses mainly on beta-lac-
tamic antibiotics, especially the association amoxicillin/clavu-
lanic acid[10]. Antibacterial therapy may be beneficial to avoid 
the development of suppurative complications such as tonsillitis, 
sinusitis, otitis media and cellulite, however delayed antibiotic 
therapy can be similarly effective in preventing complications 
when compared to immediate and empirical prescription[6,11,12] .
 Furthermore, antimicrobials are indicated in certain cir-
cumstances, such as patients who have complications (e.g. pneu-
monia and mastoiditis), who have a higher risk of developing 
complications (e.g. renal impairment) and elderly over 65 with 
cough and presenting two or more Centor criteria, or elderly 
over 80 with diabetes mellitus, hospital admission in the pre-
ceding year, history of heart failure, or under oral glucocorticoid 
treatment[13].
 This study has focused on pharyngitis and sinusitis be-
cause these are the leading causes of acute morbidity in adults 
in primary care and, the majority of cases for which antimicro-
bials are prescribed[2]. Also, URTI are differently expressed in 
children due to their susceptibility to bacterial otitis media, as-
sociated with Eustachian tube dysfunction and immaturity of the 
immune system[2-4].
 Thereby, the main objective of this study was to eval-
uate the need for antibiotic treatment, considering the presence 
of symptoms and previously known risk factors. Two research 
questions were formulated: “Is the aetiology of the infection, 
in case of antibiotic prescription, probably of bacterial origin?” 
and, “Is the prescribed antibiotic therapy for the treatment of 
URTI, necessary?” 
Methods 
Study design
 This study was implemented through a cross-sectional 
study (observational non-analytical) that included a survey with 
clinical observation of the patients. Data gathered by both means 
allowed empirical classification of the infection aetiology and 
the need for antibiotic prescription. Data collection was under-
taken between November and December of 2014.
Population and sample
 The target population included patients aged 18 or old-
er, which represent 79.76% of the total resident population in 
Portugal[14]. Paediatric patients were excluded due to specific 
clinical and treatment issues. Considering that recruitment was 
pursued in community pharmacies with a minimum capitation of 
3500 inhabitants[15], the study population considered was 2792 
inhabitants. Estimation of sample size was calculated consider-
ing a population of 2792 inhabitants, a prevalence of the phe-
nomena (p) to be 2.36%, a confidence interval (CI) of 95% and 
a beta error (d) of 3%. Thus, it was estimated that it would be 
necessary to recruit a sample (m) of 95 patients. To define the 
prevalence value (p), it was considered that the prevalence of 
patients presenting URTI is 15.7%[16]; from which 22% (ranging 
from 11 to 33%) seek health care[17], resulting in a prescription 
rate of antibiotic therapy of 68.2%[13].
Eligibility criteria for patient recruitment were as following: 
Inclusion criteria:
• Patients presenting themselves at the pharmacy where the 
study was being carried out during the study period;
• Patients presenting a prescription for antibiotic therapy;
• Patients stating to have an URTI;
Exclusion criteria were:
• Patients refusing to be submitted to a simple physical obser-
vation;
• Individuals with a prescription for others; 
• Individuals aged ≤ 18 years.
Data collection
 Data collection was performed during a face-to-face in-
terview following a questionnaire specifically designed for this 
purpose (appendix 1). This interview included a clinical obser-
vation of the patient performed in a private consultation area. 
This tool comprised three sections: I) sociodemographic charac-
terization, II) characterization of the patient’s present condition 
(self-reported signs and symptoms) and medical history, and III) 
clinical observation of signs (observed by the pharmacist). Sec-
tion II of the questionnaire was developed following the Code 
of Good Pharmaceutical Practice[18], and included information 
about the symptoms, duration thereof, presence of relevant co-
morbidities and/or prescription of other medicines that could 
affect disease progression or therapeutic selection. Patient ob-
servation included the measurement of body temperature, ob-
servation of the pharynx and tonsils, palpation of the neck (de-
tection of cervical adenopathy), palpation of the maxillary and 
frontal sinuses (pain evaluation) and the visualization of some 
signs such as rhinorrhoea and sneezing, as suggested by Centor 
criteria. Both questionnaire and patient observation enabled a 
complete information collection and were used in the establish-
ment of the probable aetiology of infection and consequent need 
for antibiotic treatment[19]. For quality assurance purposes, the 
principal investigator was submitted to a preliminary training 
period, which consisted on the clinical observation of a group of 
volunteer students, with and without symptoms of URTI, under 
the supervision of two experienced clinical pharmacists.
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Tool development
 Based on diagnostic and treatment guidelines, a scale 
was developed to empirically classify the aetiology of infections 
(Table 1) and the need for antibiotic therapy (Table 2)[11,13,20]. A 
weighting scale was defined according to the severity of signs 
and symptoms.
Ethics and confidentiality
 This study complied with the established ethical and 
legal requirements, including collection of patient informed con-
sents and the authorisation of the technical directors of the com-
munity pharmacies where the study was implemented. Patients’ 
were anonymised and the identity of the pharmacies involved 
was preserved.
Data analysis
 Data were analyzed using the Statistical Package for 
Social Sciences software (SPSS), version 20, including descrip-
tive univariate analysis of the categorical (absolute and relative 
frequencies) and scalar variables [(dispersion measures (range 
and standard deviation) and measures of central tendency (mean 
and median)]. Bivariate analysis was conducted using non-para-
metric tests (simple chi-square test and Fisher’s exact test), con-
sidering a 95% confidence interval.
Results 
 The sample included 22 patients, implying that only 
23.16% of the intended samples were recruited (95 patients). 
These were recruited in two different locations, 6 patients 
(27.3%) in Almada, Lisbon Metropolitan Area, and the remain-
ing 16 (72.7%) in Elvas, Alentejo.
Socio demographic characterization of the sample
 Most recruited patients were female, with a mean and 
median age corresponding to 38 years (σ = 16.92) and 35, re-
spectively, ranging from 19 to 78 years. Nearly half the sample 
had higher education (45.5%), although educational level in El-
vas was lower. 
Clinical and therapeutic characterization 
 On average, patients presented six symptoms ranging 
from two to eleven, as described in (Figure 1).
Figure 1: Symptoms described by patients
 During clinical observation, only one patient presented 
with fever (4.5%). The sign more often present was erythema 
of the pharynx (n=9; 40.9%). Pharyngeal exudates was present 
in 9.1% of cases (n=2). Only one patient (4.5%) revealed pain 
or tenderness in maxillary and frontal sinuses. Palpation of the 
neck resulted in the identification of 5 patients presenting an-
terior adenopathy (22.7%) (n=5) and one presenting posterior 
adenopathy (4.5%). The remaining observations revealed: rhi-
norrhoea in 7 patients (31.8%), sneezing in 2 (9.1%) and one 
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Table 1: Empirical classification of the aetiology of infection
Parameters Assigned weighting Empirical classification of the etiology of infection
Sore throat
Cervical lymphadenopathy Yes = 2 No = 0
≤3: Probable viral aetiology 
4-5: Uncertain outcome 
≥6: Probable bacterial aetiology
Pharyngeal exudate Yes = 2 No = 0
Cough Yes = 0 No = 1
Severe malaise Yes = 2 No = 0
Rhinosinusitis
Duration of symptoms ≥10 days = 2 ˂ 10 days = 0
Face pain/sensibility Yes = 1 No = 0
Purulent nasal secretions Yes = 1 No = 0
General Fever ≥ 39°C = 2 ˂ 39 °C = 0
 
Table 2: Empirical classification of the need for antibiotics
Parameters Assigned weighting Empirical classification of the need for antibiotics
Sore throat Cervical lymphadenopathy Yes = 2 No = 0
≤3: No need for antibiotic 
4-5: Uncertain outcome 
≥6: Need for antibiotic
Pharyngeal exudate Yes = 2 No = 0
Cough Yes =0 No = 1
Severe malaise Yes = 2 No = 0
Rhinosinusitis Duration of symptoms ≥10days=2 ˂10 days = 0
Face pain/sensibility Yes = 1 No = 0
Purulent nasal secretions Yes = 1 No = 0
General Fever ≥ 39°C = 2 ˂ 39°C = 0
Age ˂ 65 years =0 ≥ 65 years =1 ≥ 80 years = 2
Corticosteroid therapy Yes = 1 No = 0
4patient had signs of ocular pathology (4.5%).
 On the other hand, history of allergy and GERD were 
described in 7 (31.8%) and 2 (9.1%) patients, respectively. 
 The most often prescribed antibiotic was the macrolide, 
clarithromycin (n=8; 36.4%) (Figure 2).
Figure 2: Prescribed antibiotics for the treatment of URTI
Empirical classification of the aetiology of URTI
 Using the developed classification for aetiology of 
URTI (table 1) six patients (27.2%) were considered to present 
an infection with questionable aetiology (rating between 4 and 
5), and only one patient (4.5%) was considered to have a pos-
sible bacterial infection. The remaining sample (68.2%, n=15) 
had an empirical classification lower or equal to 3 points, which 
suggests the aetiology of the infection was probably viral. The 
prescribing pattern of antibiotics focused on amoxicillin/clavu-
lanic acid, clarithromycin and benzylpenicillin (Table 3). 
Evaluation of the need for antibiotic therapy
 Applying the second classification system, developed 
(table 2) for evaluating the need for antibiotic therapy, we found 
four patients to have a questionable result (18.2%), with clas-
sifications between 4 and 5, and only three patients (13.6%) 
evidenced the need for antibiotic treatment, presenting a rating 
above 6. Therefore, the remaining fifteen patients (68.2%) had 
ratings below 3, suggesting antibiotics were not required in these 
cases. Antibiotics prescribed for patients with probable need for 
antimicrobials were amoxicillin/clavulanic acid and clarithro-
mycin (Table 4). 
Discussion 
 Using the empirical classification of the aetiology of 
infection and considering risk factors (such as age over 65), we 
assumed to be possible to ascertain the need for antibiotic ther-
apy. Results suggest that most patients had viral infections and 
only one evidenced signs of bacterial infection. As expected, 
this study demonstrated a generalised overuse of antimicrobials, 
evidenced by the finding that only 13.6% of patients had a rat-
ing supporting antibiotic treatment[17]. Some studies suggest that 
this over prescription may be a result of patients’ expectations 
about treatment, pressuring physicians to institute the treatment 
patients believe to be more effective for URTI[9]. This suggests 
that is it important for healthcare professionals to explain pa-
tients that URTI are self-limiting infections and the overuse of 
antibiotics increases the emergence of resistances.
 Clarithromycin and azithromycin (both belonging to 
macrolide class) were prescribed in over half of the patients. 
However, according to the “Infectious Diseases Society of 
America” (IDSA) guidelines, this class of antimicrobials is 
considered second-line therapy in bacterial pharyngitis (except 
in penicillin-allergic patients)[20]. Therefore, the treatment with 
macrolides in rhinosinusitis must be discouraged due to the 
higher resistance rates of Streptococcus Pneumoniae. In addi-
tion, although benzylpenicillin is considered first-line therapy in 
bacterial pharyngitis, it was only prescribed to one patient, who 
presented an infection classified to be of doubtful aetiology. On 
the other hand, amoxicillin/clavulanic acid, which is considered 
first-line treatment in rhinosinusitis, was often prescribed in this 
study[21].
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Table 3: Prescribed treatment for patients with questionable etiology and probable bacterial infection
Empirical classification 
of the etiology of the 
infection 
Amoxicillin/ 
clavulanate   
n (%)
Clarithro-
mycin        
n (%)
Benzathine 
benzylpenicillin 
n (%)
Amox-
icillin            
n (%)
Azithromycin   
n (%)
Cefuroxime 
n (%)
Cefixime 
n (%)
Total 
n (%)
Probable viral infection 
(classification: ≤3)
3 (50.0) 5 (62.5) 0 (0.0) 1 (4.5) 4 (100.0) 1(100.0) 1 (100.0) 15 (68.2)
Doubtful etiology (clas-
sification: 4-5)
3 (50.0) 2 (25.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (27.2)
Probable bacterial infec-
tion (classification: 8)
0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.5)
Total 6 (27.3) 8 (36.4) 1 (4.5) 1 (4.5) 4 (18.2) 1 (4.5) 1 (4.5) 22 (100.0)
Table 4: Prescribed treatment according to the need for antibiotics
Classification of the 
need for antibiotics
Amoxicillin/
clavulanate 
n (%)
Claritromycin 
n (%)
Azitromycin 
n (%)
Benzathine 
benzylpenicillin 
n (%)
Amoxicillin 
n (%)
Cefuroxime 
n (%)
Cefixime 
n (%)
Total 
n (%)
Probably unnecessary 
(classification: ≤3)
3 (50.0) 5 (62.5) 4 (100.0) 0 (0.0) 1 (100.0) 1 (100.0) 1 (100.0) 15 (68.2)
Doubtful need (clas-
sification: 4-5)
1 (16.7) 2 (25.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (18.2)
Probable need (clas-
sification: ≥6)
2 (33.3) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (13.6)
Total 6 (27.3) 8 (36.4) 4 (18.2) 1 (4.5) 1 (4.5) 4 (18.2) 1 (4.5) 22 (100.0)
 Previous studies have found that in Portugal the pre-
scription pattern for antibiotics in respiratory infections focuses 
on the beta-lactamics/penicillins class, especially the combina-
tion of amoxicillin/clavulanic acid and cephalosporins, followed 
by macrolides[10,16]. Our findings support this predominance in 
one of the regions studied–Elvas. In Almada, most patients were 
prescribed a macrolide, followed by beta-lactamics.
 Cough was a prevailing symptom described by patients, 
which may indicate that these infections were not restricted to 
the upper respiratory tract, also affecting the lower tract. How-
ever, taking into account the high prevalence of smoking habits 
in this sample and considering tobacco to be the leading cause 
of chronic cough, this symptom can result from lifestyle related 
factors. Furthermore, the presence of smoking habits is a predis-
posing factor for URTI, so these patients are more susceptible to 
acquire these illnesses[22]. It is noteworthy that the prevalence of 
smoking in the sample was more than twice higher (45.5%) than 
the prevalence of smoking habits in Portugal (20.8%)[23]. 
 Despite the absence of allergic and GERD patients in 
our sample, the relationship between these conditions and URTI 
has been noticed by other authors[4,5]. However, an information 
bias must be considered because there could have been a misin-
terpretation or misunderstanding regarding the questions made 
during the interview. Also, most of the patients were from El-
vas, Alentejo, where there is an overall lower educational level 
which can justify the lack of awareness about the history of al-
lergy and GERD. 
 This study revealed some limitations, including the 
limited sample size, in comparison with the estimated 95 pa-
tients, which invalidate the extrapolation of results. This may be 
explained by the fact that when the study began, URTI were not 
at the peak season. Additionally, many people presenting a pre-
scription were not the sick patient, precluding their recruitment. 
It may be assumed that the patients able to acquire their own 
medication had the less severe clinical situations, hence the high 
prevalence of probable viral infections aetiology. The exclusion 
of patients without antimicrobial prescription prevented to esti-
mate the need for antibiotic therapy in patients who resort to the 
pharmacy when respiratory symptoms appear. Nonetheless, this 
was considered to be the best methodological option, since the 
presence of the principal investigator could have influenced the 
standard pharmaceutical intervention. The limited study period 
and human resources also contributed to the limited sample size.
It is also appropriate to reflect on the difference of the sample size 
between the two locations, which can be explained by several 
reasons. First, the greater availability to participate in the study 
in Elvas; equally important was the fact that the recruitment time 
was different in the two locations: in Elvas, it was primarily held 
during shift schedules (at night and weekend). Third, it should 
be noted that, according to data from the General Health Direc-
torate, the ambulatory antibiotic consumption is higher in Elvas 
than in other regional areas, so it can be expected an easier re-
cruitment at this location[24]. Finally, the study began in Almada, 
when URTI were not yet in seasonal peak. Consequently, due 
to the asymmetric sample size in these places, the comparative 
analysis of the data was limited, and any characterization of the 
sample recruited in Almada can also be compromised. However, 
this study was based on developing clinical competencies of a 
pharmacy student and as such, had to be feasible and compatible 
with classes, explaining the methodological option taken.
 The methodology used to classify the aetiology of in-
fections and assess the need and appropriateness of the therapy 
is questionable for various reasons. For example, the presence 
of fever may have been underestimated because many patients 
were under antipyretic medication effect. It should also be borne 
in mind that the questionnaire did not include information con-
cerning beta-lactamic antibiotic allergy, so it is not possible to 
establish if some of the prevailing prescription of macrolides 
is due to the presence of allergic patients. The scale was tested 
but not validated, which means that the sensitivity and speci-
ficity are unknown. Nonetheless, these scales are pioneers, de-
veloped through international guidelines, so it would be an as-
set to validate them on a representative sample, in the future. 
Despite having received a differentiated training the principal 
investigator was, at the time, a practicing pharmacist and his 
experience in observation was certainly lower than of a doctor 
and consequently some ratings may be subject to error or dis-
cussion. Nonetheless, we believe it was a valuable experience 
for the student to develop his clinical competencies further, and 
also for the pharmacy to have the opportunity to provide patients 
with an advanced service, currently not offered in most pharma-
cies (a complete clinical evaluation including observation when 
presenting minor symptoms). This pitfall of the system is not 
restricted to pharmacies but generalised in primary care, where 
doctors for many reasons do not have the opportunity to conduct 
a thorough and complete evaluation of the signs and symptoms, 
as mentioned by some patients during this study[9].
 Despite the aforementioned limitations, this study fo-
cuses on a relevant topic, introducing an innovative approach 
to pharmaceutical interventions, and presents results consistent 
with previous studies, highlighting the overuse of antimicrobials, 
particularly in sore throat[10]. This suggests that the campaigns 
developed to promote the rational use of antibiotics, although 
important, are insufficient to change behaviours and could ben-
efit from pharmacists’ intervention, a professional privileged by 
its trained skills and unique position in the healthcare system. 
These interventions could be fostered by studies like this. 
Conclusion 
 Antibiotic treatment prescribed in most clinical situa-
tions was probably unnecessary, since the analysed URTI did not 
suggest a bacterial aetiology. Clarithromycin and amoxicillin/
clavulanic acid revealed a high indication. Hence, it is essential 
to adopt corrective measures in primary care to promote the ra-
tional use of antimicrobials, in order to fight the emergence of 
resistance and further decrease treatment costs. 
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